Revance Therapeutics Inc (NASDAQ: RVNC) kicked off on Friday, down -4.13% from the previous trading day, before settling in for the closing price of $3.39. Over the past 52 weeks, RVNC has traded in a range of $2.30-$7.59.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 1041.31% over the last five years. While this was happening, its average annual earnings per share was recorded 42.40%. With a float of $95.29 million, this company’s outstanding shares have now reached $104.90 million.
The firm has a total of 597 workers. Let’s measure their productivity. In terms of profitability, gross margin is 70.66%, operating margin of -67.21%, and the pretax margin is -72.59%.
Revance Therapeutics Inc (RVNC) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Revance Therapeutics Inc is 8.71%, while institutional ownership is 80.80%. The most recent insider transaction that took place on Nov 18 ’24, was worth 16,296. In this transaction CMO & Global Therapeutics Lead of this company sold 3,908 shares at a rate of $4.17, taking the stock ownership to the 104,945 shares. Before that another transaction happened on Apr 16 ’24, when Company’s Chief Commercial Officer sold 2,392 for $3.80, making the entire transaction worth $9,096. This insider now owns 114,864 shares in total.
Revance Therapeutics Inc (RVNC) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.3 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.40% per share during the next fiscal year.
Revance Therapeutics Inc (NASDAQ: RVNC) Trading Performance Indicators
Take a look at Revance Therapeutics Inc’s (RVNC) current performance indicators. Last quarter, stock had a quick ratio of 3.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.92, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Revance Therapeutics Inc (RVNC)
Analysing the last 5-days average volume posted by the [Revance Therapeutics Inc, RVNC], we can find that recorded value of 4.68 million was better than the volume posted last year of 4.45 million. As of the previous 9 days, the stock’s Stochastic %D was 54.02%. Additionally, its Average True Range was 0.15.
During the past 100 days, Revance Therapeutics Inc’s (RVNC) raw stochastic average was set at 6.59%, which indicates a significant decrease from 37.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.02% in the past 14 days, which was lower than the 102.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.87, while its 200-day Moving Average is $4.23. Now, the first resistance to watch is $3.31. This is followed by the second major resistance level at $3.38. The third major resistance level sits at $3.42. If the price goes on to break the first support level at $3.21, it is likely to go to the next support level at $3.17. Now, if the price goes above the second support level, the third support stands at $3.10.
Revance Therapeutics Inc (NASDAQ: RVNC) Key Stats
The company with the Market Capitalisation of 339.27 million has total of 104,390K Shares Outstanding. Its annual sales at the moment are 234,040 K in contrast with the sum of -323,990 K annual income. Company’s last quarter sales were recorded 59,880 K and last quarter income was -38,120 K.
